Lv1
30 积分 2024-11-17 加入
Ibrutinib-induced Sweet syndrome
21天前
已关闭
Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study
21天前
已完结
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial
21天前
已完结
Orelabrutinib for systemic lupus erythematosus: A randomised, double-blind, placebo-controlled study
1个月前
已完结
Chemistry, pharmacology and spotlight on the clinical trials of remibrutinib: a first in class, oral Bruton’s tyrosine kinase (BTK) inhibitor for chronic spontaneous urticaria
1个月前
已完结
Comparative Risk of Adverse Cardiovascular Outcomes With Zanubrutinib Versus Ibrutinib in B-Cell Malignancies: A Large Real-World Propensity-Matched Analysis
1个月前
已完结
Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
1个月前
已完结
Rituximab, Acalabrutinib, and Durvalumab for Primary Central Nervous System Lymphoma: A Single-arm, Phase 1b, Multi-center Study
1个月前
已完结
Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study
1个月前
已完结
A real-world multicenter study of first-line zanubrutinib-based therapy for diffuse large B-cell lymphoma
1个月前
已完结
皖公网安备34019202002308
